Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $70.00

Definium Therapeutics (NASDAQ:DFTX) had its target price lifted by Royal Bank Of Canada from $66.00 to $70.00 in a research note released on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other equities analysts have also recently issued reports about the stock. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of Definium Therapeutics in a research note on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $66.24.

Definium Therapeutics Stock Performance

DFTX opened at $33.00 on Tuesday. Definium Therapeutics has a 12-month low of $10.46 and a 12-month high of $49.70. The stock has a market cap of $4.43 billion, a price-to-earnings ratio of -10.61 and a beta of 2.23. The business has a 50 day moving average of $36.19 and a 200-day moving average of $30.31. The company has a quick ratio of 6.95, a current ratio of 15.53 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.09. On average, equities research analysts expect that Definium Therapeutics will post -2.94 earnings per share for the current year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,377 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the transaction, the chief financial officer owned 394,528 shares in the company, valued at $14,427,888.96. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew T. Wiley sold 3,097 shares of Definium Therapeutics stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the sale, the insider directly owned 359,036 shares of the company’s stock, valued at $13,129,946.52. This represents a 0.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 71,098 shares of company stock valued at $2,626,115. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. First Trust Advisors LP raised its stake in Definium Therapeutics by 38.8% in the 3rd quarter. First Trust Advisors LP now owns 13,222 shares of the company’s stock worth $503,000 after purchasing an additional 3,695 shares in the last quarter. Creek Drive Management Group LLC acquired a new position in shares of Definium Therapeutics during the 3rd quarter worth approximately $1,182,000. Voya Investment Management LLC grew its position in shares of Definium Therapeutics by 74.9% during the 3rd quarter. Voya Investment Management LLC now owns 166,443 shares of the company’s stock worth $6,335,000 after purchasing an additional 71,277 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Definium Therapeutics by 10.3% during the third quarter. HighTower Advisors LLC now owns 24,619 shares of the company’s stock worth $937,000 after purchasing an additional 2,306 shares during the period. Finally, Bessemer Group Inc. bought a new position in shares of Definium Therapeutics during the third quarter worth approximately $42,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.